Project Grant R03CA292953
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$175K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $606,839 to Weill Medical College of Cornell University to study the role of microbiota amino acid metabolism in cancer. The project aims to identify gut microbes and their genes that deplete intestinal amino acids, and evaluate how they affect the tumor microenvironment and cancer progression. The 5-year project will combine bioinformatics, metabolomics,...
This Project Grant award, valued at $150,701.00 and provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), aims to investigate the relationship between diet, gut microbiome, and cancer treatment-related cognitive impairment (CRCI) in breast cancer survivors (BCS) undergoing chemotherapy. The key objectives are to: 1) determine the relationship between components of a Mediterranean diet, gut microbiome, and cognitive function in 30 BCS before, during, and...
The National Cancer Institute (NCI) awarded a $425,573 Project Grant (CFDA 93.395 Cancer Treatment Research) to Magee-Womens Research Institute and Foundation located in Pittsburgh, Pennsylvania. The grant will fund a 2-year study (July 1, 2025 - June 30, 2027) to identify gut bacteria species, metabolites, and metabolic pathways associated with high mammographic breast density (MBD). The goal is to provide insights into modifiable factors that contribute to high MBD, which is a significant risk...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $678,399 to The University of Texas MD Anderson Cancer Center to conduct a prebiotic diet intervention study. The goal is to evaluate whether a prebiotic-enriched diet can enhance the gut microbiome and improve response to immune checkpoint inhibitor (ICI) therapy in patients with metastatic melanoma. The 5-year study will investigate the...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $426,425 to Baylor College of Medicine to conduct a pilot study examining the relationship between gut microbiome composition, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatocellular carcinoma (HCC). The key objectives of this 2-year study are to: 1) characterize baseline gut microbiome diversity associated with MASLD with and without HCC, 2)...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to develop a first-of-its-kind intervention against colorectal cancer associated with colibactin-producing bacteria. The $627,422 award to the Regents of the University of Michigan will fund research to engineer E. coli bacteria to display an enzyme that can neutralize the genotoxin colibactin, thereby preventing DNA damage and tumorigenesis. The 5-year project will optimize the surface...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $179,988.00 to The Leland Stanford Junior University (Stanford University) to conduct research on modulating the human gut microbiome to enhance immune responses against cancer. The goal is to identify bacterial functions that can improve the efficacy of cancer immunotherapy, specifically immune checkpoint blockade therapies. The research plan involves aggregating and analyzing...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $281,606 to New York University School of Medicine to conduct research aimed at harnessing gut-derived bacteria to drive anti-tumor immunity in lung cancer. The 5-year project, led by Dr. Rabi Upadhyay, an Assistant Professor at NYU, will investigate the mechanism by which certain gut commensals can trigger systemic anti-tumor immune responses, even in the absence...
The Project Grant award of $300,000.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support a study on the epidemiology of the gut-liver axis and its relationship to hepatocellular carcinoma (HCC) risk in a multiethnic liver cirrhosis cohort. The study aims to expand the existing Microbiome, Microbial Markers, and Liver Disease (M3LD) cohort by enrolling approximately 1,000 participants with liver cirrhosis, with a focus on...
This $626,893 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Texas MD Anderson Cancer Center will fund research to study the role of bacterial-colonized microniches within tumors and their impact on intratumoral heterogeneity. The research aims to: 1) functionally map the cellular and metabolic features of these bacterial microniches within patient tumor tissues, 2) delineate the human cell types harboring intracellular...